Severe Hepatocellular Dysfunction following Cyproterone Acetate Therapy

B. T. PARYS, Saeed Hamid, R. G. Thomson

British Journal of Urology · 1991 · 39 citations · 2 references

Concepts

Abstract

Cyproterone acetate (CPA) is a widely used drug in the treatment of advanced prostatic carcinoma. Although it is generally well tolerated, liver toxicity has been recognised as a complication of long-term use. We report 3 patients with severe hepatocellular damage due to CPA therapy, 2 with fatal fulminant hepatitis.

References

2